Evaluation of the conjoint efficacy in Chinese medicine with the longitudinal latent variable linear mixed model

被引:0
作者
Dan-hui Yi
Yang Li
Shu-xin Shao
Yan-ming Xie
Ya Yuwen
机构
[1] Renmin University of China,Center for Applied Statistics
[2] Renmin University of China,International College (Suzhou Research Institute)
[3] Renmin University of China,School of Statistics
[4] Yale University,School of Public Health
[5] Columbia University,Graduate School of Business
[6] China Academy of Chinese Medical Sciences,Institute of Basic Research in Clinical Medicine
来源
Chinese Journal of Integrative Medicine | 2013年 / 19卷
关键词
Chinese medicine; efficacy evaluation; multiple endpoints; longitudinal data; latent variable; ischemic stroke;
D O I
暂无
中图分类号
学科分类号
摘要
Chinese medicine (CM) clinical efficacy evaluation research involves the longitudinal multivariate measurement which means that patients are measured repeatedly and each patient is measured by several indicators on each fixed cross-section. Although each indicator can be evaluated separately with a longitudinal linear mixed model, it is important to consider all the endpoints together especially when researchers pay special attention to the change of the conjoint efficacy for several indicators in one patient. In this article, we introduce a latent variable linear mixed model to the CM conjoint efficacy evaluation and discuss why and how to analyze the longitudinal multivariate endpoint data in the clinical CM efficacy evaluation research. It may lead to the new insight of using such methodology in the field of conjoint efficacy evaluating of CM study. And with the definition of syndrome and symptom in the CM theory, the applied discussion brings the insight of CM syndrome evaluating in future. We illustrate this methodology using an example of CM efficacy evaluation from an ischemic stroke research.
引用
收藏
页码:629 / 635
页数:6
相关论文
共 40 条
  • [1] Legler J(1995)Efficiency and power of tests for multiple binary outcomes J Am Stat Assoc 90 680-693
  • [2] Lefkopoulou M(2004)Design and analysis of group sequential clinical trials with multiple primary Endpoints Biometrics 60 134-145
  • [3] Ryan L(2007)Multiple co-primary endpoints: medical and statistical solutions Drug Inf J 41 31-46
  • [4] Kosorok MR(2007)Partition testing in dose-response studies with multiple endpoints Pharm Stat 6 181-192
  • [5] Shi YJ(1992)Bivariate latent variable models for clustered discrete and continuous outcomes J Am Stat Assoc 87 651-658
  • [6] Demets DL(1996)Latent variable models with fixed effects Biometrics 52 650-663
  • [7] Offen WW(2000)Latent variable models for longitudinal data and multiple continuous outcomes Biometrics 56 1047-1054
  • [8] Chuang-Stein C(2002)Analysis of multivariate longitudinal outcomes with nonignorable dropouts and missing covariates: changes in methadone treatment practices J Am Stat Assoc 97 40-52
  • [9] Dmitrienko A(1986)The standard for diagnosis and efficacy evaluation of stroke in TCM (draft) Chin J Tradit Chin Med Pharm (Chin) 1 120-121
  • [10] Littman G(1996)The TCM diagnosis and efficacy evaluation standard for stroke J Beijing Univ Tradit Chin Med (Chin) 19 55-56